Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Trial details
- Registry ID
- NCT05549297
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)NCT05549297 | Immunocore Ltd | Phase 3 | Recruiting | 2028-03Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |